Patents by Inventor Laura Serino
Laura Serino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10988511Abstract: Homologs of the E. coli proteins orf353, bacterial lg-like domain (group 1) protein (orf405), flu antigen 43 (orf1 364), NodT-family outer-membrane-factor-lipoprotein efflux transporter (orf1 767), gspK (orf3515), gspJ (orf3516), toriB-dependent siderophore receptor (orO597), fibrial protein (orf3613), upec-948, upec-1232. A chain precursor of the type-1 fimbria! protein (upec-1875), yapH homolog (upec-2820), hemolysin A (recp-3768), and Sel 1 repeat-containing protein (upec-521 1) from several pathogenic strains of E. coli have been identified with regions within the proteins that are conserved across all E. coli. Fragments corresponding to the conserved regions, especially immunogenic fragments such a linear B-epitopes, are provided.Type: GrantFiled: July 7, 2010Date of Patent: April 27, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Laura Serino, Maria Rita Fontana, Danilo Gomes Moriel
-
Patent number: 10105429Abstract: The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.Type: GrantFiled: December 5, 2016Date of Patent: October 23, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Laura Serino, Mariagrazia Pizza
-
Publication number: 20180298064Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: June 26, 2018Publication date: October 18, 2018Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Hervé TETTELIN
-
Patent number: 10058600Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.Type: GrantFiled: October 27, 2014Date of Patent: August 28, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Laura Serino, Maria Rita Fontana, Danilo Gomes Moriel
-
Patent number: 10035826Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.Type: GrantFiled: May 9, 2016Date of Patent: July 31, 2018Assignees: GlaxoSmithKline Biologicals SA, J. Craig Venture Institute, Inc.Inventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Publication number: 20170296643Abstract: The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.Type: ApplicationFiled: December 5, 2016Publication date: October 19, 2017Applicant: GlaxoSmithKline Biologicals SAInventors: Laura SERINO, Mariagrazia PIZZA
-
Patent number: 9511130Abstract: The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.Type: GrantFiled: September 14, 2012Date of Patent: December 6, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Laura Serino, Mariagrazia Pizza
-
Publication number: 20160244489Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: May 9, 2016Publication date: August 25, 2016Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
-
Patent number: 9334313Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.Type: GrantFiled: June 2, 2014Date of Patent: May 10, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Patent number: 9173954Abstract: E. coli proteins have been identified that are useful as carrier proteins to improve a response to a polysaccharide immunogen conjugated to such protein. In particular, AcfD precursor protein (orf3526 polypeptide), Flu antigen 43 protein (orf1364 polypeptide), and Sel1 repeat-containing protein (upec-5211 polypeptide) have been shown to be effective. Additionally, these E. coli proteins can enhance the immune response to glucans, particularly fungal glucans.Type: GrantFiled: December 30, 2010Date of Patent: November 3, 2015Assignee: GlaxoSmithKline Biologicals SAInventors: Paolo Costantino, Francesco Berti, Francesca Micoli, Anna Kabanova, Laura Serino, Maria Rosaria Romano, Marta Tontini
-
Patent number: 9101560Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.Type: GrantFiled: May 29, 2013Date of Patent: August 11, 2015Assignee: GlaxoSmithKline Biologicals SAInventors: Laura Serino, Mariagrazia Pizza, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20150118261Abstract: The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.Type: ApplicationFiled: September 14, 2012Publication date: April 30, 2015Applicant: Novartis AGInventors: Laura Serino, Mariagrazia Pizza
-
Publication number: 20150110830Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.Type: ApplicationFiled: October 27, 2014Publication date: April 23, 2015Inventors: Laura SERINO, Maria Rita FONTANA, Danilo GOMES MORIEL
-
Publication number: 20140356389Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
-
Patent number: 8871214Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.Type: GrantFiled: July 16, 2010Date of Patent: October 28, 2014Assignee: Novartis AGInventors: Laura Serino, Danilo Gomes Moriel, Maria Rita Fontana
-
Patent number: 8758764Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: GrantFiled: February 17, 2006Date of Patent: June 24, 2014Assignees: Novartis Vaccines and Diagnostics Srl, J. Craig Venter InstituteInventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Publication number: 20130323274Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Applicant: NOVARTIS AGInventors: Laura SERINO, Mariagrazia PIZZA, Danilo GOMES MORIEL, Maria Rita FONTANA
-
Patent number: 8470341Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.Type: GrantFiled: February 23, 2009Date of Patent: June 25, 2013Assignee: Novartis AGInventors: Laura Serino, Mariagrazia Pizza, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20130004531Abstract: Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic E. coli strains. The polypeptides have cellular locations which render them accessible to the immune system. The genes encoding the polypeptides were initially identified as being present in uropathogenic strain 536 but absent from non-pathogenic strains.Type: ApplicationFiled: September 4, 2012Publication date: January 3, 2013Applicants: Robert Koch Institute, Novartis Vaccines and Diagnostics SRLInventors: Francesco BERLANDA SCORZA, Maria Rita Fontana, Danilo Gomes Moriel, Mariagrazia Pizza, Laura Serino, Jörg Hacker
-
Publication number: 20120308600Abstract: E. coli proteins have been identified that are useful as carrier proteins to improve a response to a polysaccharide immunogen conjugated to such protein. In particular, AcfD precursor protein (orf3526 polypeptide), Flu antigen 43 protein (orf1364 polypeptide), and Sel1 repeat-containing protein (upec-5211 polypeptide) have been shown to be effective. Additionally, these E. coli proteins can enhance the immune response to glucans, particularly fungal glucans.Type: ApplicationFiled: December 30, 2010Publication date: December 6, 2012Applicant: Novartis AGInventors: Paolo Costantino, Francesco Berti, Francesca Micoli, Anna Kasanova, Laura Serino, Maria Rosaria Romano, Marta Tortini